Kiniksa Pharmaceuticals International PLC
KNSA42.000USD
-0.490-1.15%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.17BMarket Cap
86.36P/E TTM
More Details of Kiniksa Pharmaceuticals International PLC Company
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Kiniksa Pharmaceuticals International PLC Info
Ticker SymbolKNSA
Company nameKiniksa Pharmaceuticals International PLC
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Number of employees315
Security typeOrdinary Share
Fiscal year-endMay 24
Address23 Old Bond Street, Floor 3
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWIS 4PZ
Phone
Websitehttps://www.kiniksa.com/
Ticker SymbolKNSA
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Company Executives of Kiniksa Pharmaceuticals International PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
109.80K
-50.45%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
22.71K
-20.81%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
109.80K
-50.45%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.09K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
22.71K
-20.81%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
156.51M
99.81%
United Kingdom
291.00K
0.19%
Rest oF World
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.86%
The Vanguard Group, Inc.
6.77%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
Other
69.04%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.86%
The Vanguard Group, Inc.
6.77%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
Other
69.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.22%
Investment Advisor/Hedge Fund
23.79%
Investment Advisor
18.70%
Research Firm
7.63%
Individual Investor
3.34%
Pension Fund
0.47%
Bank and Trust
0.18%
Family Office
0.10%
Corporation
0.02%
Other
4.55%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
419
40.93M
90.64%
-3.92M
2025Q2
396
42.64M
98.10%
-1.50M
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
3.91M
8.99%
+526.57K
+15.56%
Jun 30, 2025
The Vanguard Group, Inc.
3.12M
7.19%
-225.66K
-6.74%
Jun 30, 2025
Baker Bros. Advisors LP
2.82M
6.5%
+6.35K
+0.23%
Jun 30, 2025
Tang Capital Management, LLC
2.33M
5.36%
+210.03K
+9.91%
Jun 30, 2025
Fairmount Funds Management LLC
1.77M
4.08%
+670.59K
+60.84%
Jun 30, 2025
Acadian Asset Management LLC
1.27M
2.92%
+233.67K
+22.59%
Jun 30, 2025
D. E. Shaw & Co., L.P.
791.30K
1.82%
+393.56K
+98.95%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
735.42K
1.69%
+735.42K
--
Jun 30, 2025
Desnick (Robert)
1.05M
2.42%
--
--
Apr 08, 2025
Millennium Management LLC
1.02M
2.35%
+172.84K
+20.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.14%
First Trust Active Factor Small Cap ETF
0.7%
iShares Health Innovation Active ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.22%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.21%
WisdomTree US SmallCap Fund
0.21%
WisdomTree US SmallCap Quality Growth Fund
0.18%
Invesco Nasdaq Biotechnology ETF
0.16%
Fidelity Enhanced Small Cap ETF
0.14%
Strive Small-Cap ETF
0.07%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.14%
First Trust Active Factor Small Cap ETF
Proportion0.7%
iShares Health Innovation Active ETF
Proportion0.38%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.21%
WisdomTree US SmallCap Fund
Proportion0.21%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.18%
Invesco Nasdaq Biotechnology ETF
Proportion0.16%
Fidelity Enhanced Small Cap ETF
Proportion0.14%
Strive Small-Cap ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kiniksa Pharmaceuticals International PLC?
The top five shareholders of Kiniksa Pharmaceuticals International PLC are:
Rubric Capital Management LP holds 3.91M shares, accounting for 8.99% of the total shares.
The Vanguard Group, Inc. holds 3.12M shares, accounting for 7.19% of the total shares.
Baker Bros. Advisors LP holds 2.82M shares, accounting for 6.50% of the total shares.
Tang Capital Management, LLC holds 2.33M shares, accounting for 5.36% of the total shares.
Fairmount Funds Management LLC holds 1.77M shares, accounting for 4.08% of the total shares.
Rubric Capital Management LP holds 3.91M shares, accounting for 8.99% of the total shares.
The Vanguard Group, Inc. holds 3.12M shares, accounting for 7.19% of the total shares.
Baker Bros. Advisors LP holds 2.82M shares, accounting for 6.50% of the total shares.
Tang Capital Management, LLC holds 2.33M shares, accounting for 5.36% of the total shares.
Fairmount Funds Management LLC holds 1.77M shares, accounting for 4.08% of the total shares.
What are the top three shareholder types of Kiniksa Pharmaceuticals International PLC?
The top three shareholder types of Kiniksa Pharmaceuticals International PLC are:
Rubric Capital Management LP
The Vanguard Group, Inc.
Baker Bros. Advisors LP
Rubric Capital Management LP
The Vanguard Group, Inc.
Baker Bros. Advisors LP
How many institutions hold shares of Kiniksa Pharmaceuticals International PLC (KNSA)?
As of 2025Q3, 419 institutions hold shares of Kiniksa Pharmaceuticals International PLC, with a combined market value of approximately 40.93M, accounting for 90.64% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.46%.
What is the biggest source of revenue for Kiniksa Pharmaceuticals International PLC?
In FY2025Q2, the -- business generated the highest revenue for Kiniksa Pharmaceuticals International PLC, amounting to -- and accounting for --% of total revenue.
